Physician profile
Kashif Irfan
NPI 1851351977
$25,680.62
in general payments reported to CMS, 2019-2025
62 companies · $4,041 in 2025
The $4,041 reported for 2025 was more than what 89% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,187 · 2020: $2,862 · 2021: $3,623 · 2022: $2,397 · 2023: $2,991 · 2024: $5,581 · 2025: $4,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Travel and Lodging: $561 · Education: $62.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,988.37 |
| Travel and Lodging | $560.97 |
| Education | $62.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,723.26 | 2019-2025 | Proclaim, Eterna |
| Boston Scientific Corporation | $2,304.63 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Medtronic, INC. | $1,931.32 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Forte Bio-Pharma LLC | $1,689.67 | 2020-2025 | Prolate, Nalocet, Tanlor |
| Spinal Simplicity, LLC | $1,467.85 | 2023-2025 | Ha Minuteman G3-R, Liberty Si |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,457.18 | 2021-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $1,269.82 | 2019-2025 | Belbuca, Xtampza |
| Abbvie INC. | $1,149.81 | 2021-2025 | |
| Scilex Pharmaceuticals INC. | $1,087.51 | 2019-2025 | Ztlido |
| Biohaven Pharmaceuticals, INC. | $882.59 | 2020-2021 | |
| Pfizer INC. | $865.05 | 2019-2025 | |
| Curonix LLC | $712.27 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Amgen INC. | $709.07 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $660.60 | 2019-2024 | Ajovy |
| Horizon Therapeutics Plc | $625.27 | 2019-2022 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kashif Irfan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.